


Adams and List. The awards, for the best student first-authored abstracts, were presented to Daniel H. Cox, Tufts Medical School, for an abstract entitled "Calcium Channel Modulation by Norepinephrine and GABA," and Beth B. Hogans, University of Maryland School of Medicine, for an abstract entitled "Calcium Permeation of Voltage-Dependent Sodium Channels at Large Driving Forces."

**1991 APS Conference Registration  
"From Channels to Cross Bridges"**

Registration Category	Total
APS Members	56
APS Retired Members	5
Nonmembers	132
Invited Speakers	51
Students	33
Guests	12
<b>TOTAL</b>	<b>289</b>



(l-r) D. H. Cox, Sir Andrew Huxley, S. G. Schultz, B. B. Hogans



Poster Sessions

**Know Your Sustaining Associates**

**Fisons Pharmaceuticals**

The Pharmaceutical Division of Fisons is an international research-based pharmaceutical company committed to provide excellent health care products for prescription and consumer use. Fisons develops and manufactures a wide variety of pharmaceutical products, with markets in more than 100 countries. Fisons is recognized as a world leader in the treatment of respiratory problems and allergies and also markets products for cardiovascular disorders, neurological diseases, and dermatological problems. Fisons has a major commitment to research and development to generate superior future medicines for these and other therapeutic areas including immunological and metabolic diseases.

**R. W. Johnson  
Pharmaceutical  
Research Institute**

Established in 1988, the R. W. Johnson Pharmaceutical Research Institute (PRI) pools the research and development resources of five successful Johnson & Johnson companies into a single worldwide, world-class R & D organization.

PRI integrates the considerable research achievements and potential of groups that were previously associated with McNeil Pharmaceutical, Ortho Pharmaceutical Corporation, Ortho Biotech, Johnson & Johnson Biotechnology Center, and Cilag International Research Center. Already one of the strongest pharmaceutical R & D com-

panies in the world, PRI has forged alliances with other research organizations worldwide to accelerate drug discovery efforts.

Research and development at PRI focuses on reproductive medicine, dermatology, hematology/oncology, immunological disorders, central nervous system disorders, and infectious diseases, among other therapeutic areas. The world's best and brightest in science and medicine are working at PRI to discover and develop pharmaceutical and biotechnological products that will enhance health and life.